COLL - Collegium Pharmaceutical - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.172B

Cash

325.5M

Avg Qtr Burn

N/A

Short % of Float

20.82%

Insider Ownership

0.83%

Institutional Own.

-

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nucynta (tapentadol) Tablets / Extended-Release Tablets Details Pain, Acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Belbuca (Buprenorphine) Details Chronic pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Xtampza ER (oxycodone) Details Pain, Acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELYXYBTM (celecoxib oral solution) Details Migraines	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Symproic (naldemedine) Details Opioid induced constipation, Bowel preparation	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.